title: Profile of olaparib in the treatment of advanced ovarian cancer.
abstract: Olaparib is a poly(ADP-ribose) polymerase inhibitor that received accelerated approval from the US Food and Drug Administration as monotherapy for patients with germline BRCA mutations and ovarian cancer treated with three or more prior lines of chemotherapy. This article summarizes the mechanism of poly(ADP-ribose) polymerase inhibition, therapeutic profile and uses of olaparib, and current and ongoing literature pertaining to olaparib in advanced ovarian cancer.
authors.affiliation: Division of Gynecologic Oncology, The University of Arizona Cancer Center, Phoenix, AZ; Division of Gynecologic Oncology, St Joseph's Hospital and Medical Center, Phoenix, AZ.
authors.forename: Dana M
authors.initials: DM
authors.lastname: Chase
authors.affiliation: Division of Gynecologic Oncology, St Joseph's Hospital and Medical Center, Phoenix, AZ; Creighton University School of Medicine, St Joseph's Hospital and Medical Center, Phoenix, AZ.
authors.forename: Shreya
authors.initials: S
authors.lastname: Patel
authors.affiliation: Department of Trauma, Critical Care, and Acute Care Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: Kristin
authors.initials: K
authors.lastname: Shields
keywords: PARP; olaparib; ovarian cancer